G-CSF is not necessary to maintain over 99% dose?intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis-Reference-Cited by-同舟云学术

G-CSF is not necessary to maintain over 99% dose?intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis

Published:2007-06 Issue:6 Volume:137 Page:545-552
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Evens Andrew M.,Cilley Jeffrey,Ortiz Taylor,Gounder Mrinal,Hou Nanjiang,Rademaker Alfred,Miyata Sarah,Catsaros Kara,Augustyniak Connie,Bennett Charles L,Tallman Martin S.,Variakojis Daina,Winter Jane N.,Gordon Leo I.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2007.06598.x/fullpdf

Reference28 articles.

1. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors

2. ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results

3. Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD

4. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

5. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305);Cancer Science;2024-07-22

2. Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma;British Journal of Haematology;2024-05-02

3. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium;Journal of Clinical Oncology;2023-04-10

4. The effect of concomitant use of Colony-Stimulating factors on bleomycin pulmonary toxicity – A systematic review and meta-analysis;International Immunopharmacology;2022-11

5. Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance;Internal Medicine Journal;2021-11-22